Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy.
暂无分享,去创建一个
[1] K. Brouwer,et al. Toxicokinetics of Intravenous Methanol in the Female Rat , 1993 .
[2] R. Hider,et al. Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. , 1993, Drug metabolism and disposition: the biological fate of chemicals.
[3] S. Sandroni,et al. Aluminium intoxication in undialysed adults with chronic renal failure. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[4] C. Orvig,et al. 1-n-Propyl- and 1-n-butyl-3-hydroxy-2-methyl-4-pyridinone complexes of group 13 (IIIA) metal ions , 1991 .
[5] E. G. Jackson,et al. Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum. , 1991, The Journal of pharmacology and experimental therapeutics.
[6] U. Ungerstedt,et al. Aluminum distribution into brain and liver of rats and rabbits following intravenous aluminum lactate or citrate: a microdialysis study. , 1991, Toxicology and applied pharmacology.
[7] E. Huehns,et al. The Development of Hydroxypyridin‐4‐ones as Orally Active Iron Chelators , 1990, Annals of the New York Academy of Sciences.
[8] R. Puniyani,et al. Oral iron chelation with L1 , 1990, The Lancet.
[9] C. Orvig,et al. Comparison of ligands of differing denticity and basicity for the in vivo chelation of aluminium and gallium , 1990 .
[10] C. Orvig,et al. Aluminum and gallium complexes of 1-ethyl-3-hydroxy-2-methyl-4-pyridinone: a new exoclathrate matrix , 1989 .
[11] C. Orvig,et al. The complexation of aluminum with N-substituted 3-hydroxy-4-pyridinones , 1989 .
[12] R. Hider,et al. Investigation of the anti-inflammatory properties of hydroxypyridinones. , 1989, Annals of the rheumatic diseases.
[13] P. Harrison,et al. Release of iron from ferritin molecules and their iron-cores by 3-hydroxypyridinone chelators in vitro. , 1989, Journal of Inorganic Biochemistry.
[14] R. Yokel. Aluminum and Alzheimer's Disease: Should We Worry? , 1988 .
[15] P. McNamara,et al. Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. , 1988, Toxicology and applied pharmacology.
[16] C. Orvig,et al. Aluminum and gallium compounds of 3-hydroxy-4-pyridinones: synthesis, characterization, and crystallography of biologically active complexes with unusual hydrogen bonding , 1988 .
[17] G. Kontoghiorghes,et al. Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones , 1987 .
[18] E. Chew,et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.
[19] M. Tichy̌,et al. QSAR Analysis and Data Extrapolation among Mammals in a Series of Aliphatic Alcohols , 1985 .
[20] J. Lunec,et al. Cerebral and ocular toxicity induced by desferrioxamine. , 1985, The Quarterly journal of medicine.
[21] S. Colan,et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. , 1985, The New England journal of medicine.
[22] V. Parsons,et al. Aluminium-induced anaemia in haemodialysis patients. , 1985, Nephron.
[23] A. Sedman,et al. Encephalopathy in childhood secondary to aluminum toxicity. , 1984, The Journal of pediatrics.
[24] G. Arden,et al. OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINE , 1983, The Lancet.
[25] S. Ott,et al. The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. , 1982, The New England journal of medicine.
[26] S. Sideman,et al. The dialysis dementia syndrome and aluminum intoxication. , 1982, Nephron.
[27] O. Oster. The aluminium content of human serum determined by atomic absorption spectroscopy with a graphite furnace. , 1981, Clinica chimica acta; international journal of clinical chemistry.
[28] A. Alfrey,et al. Metabolism and toxicity of aluminum in renal failure. , 1980, The American journal of clinical nutrition.
[29] W. D. Kaehny,et al. The dialysis encephalopathy syndrome. Possible aluminum intoxication. , 1976, The New England journal of medicine.
[30] O. Röe. THE METABOLISM AND TOXICITY OF METHANOL , 1955 .